Securin enhances the anti-cancer effects of 6-methoxy-3-(3′,4′,5′-trimethoxy-benzoyl)-1H-indole (BPR0L075) in human colorectal cancer cells

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Tseng, Ho Hsing ^a   Chuah, Qiu Yu ^a   Yang, Pei Ming ^b   Chen, Chiung Tong ^c   Chao, Jung Chi ^a   Lin, Ming Der ^a   Chiu, Shu Jun ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXY 3 (3',4',5' TRIMETHOXY BENZOYL) 1H INDOLE; ANTINEOPLASTIC AGENT; BPR 0L075; CASPASE; CYCLIN DEPENDENT KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; SECURIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; 6 METHOXY 3 (3',4',5' TRIMETHOXYBENZOYL) 1H INDOLE; 6-METHOXY-3-(3',4',5'-TRIMETHOXYBENZOYL)-1H-INDOLE; INDOLE DERIVATIVE; PITUITARY TUMOR TRANSFORMING PROTEINS; PITUITARY TUMOR-TRANSFORMING PROTEINS; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ACTIVATION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CHEMOSENSITIVITY; COLORECTAL CANCER; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS SPINDLE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; UPREGULATION; APOPTOSIS; CELL STRAIN HCT116; COLORECTAL TUMOR; DNA REPAIR; G2 PHASE CELL CYCLE CHECKPOINT; GENETICS; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CDC2 PROTEIN KINASE; COLORECTAL NEOPLASMS; DNA REPAIR; G2 PHASE CELL CYCLE CHECKPOINTS; HCT116 CELLS; HUMANS; INDOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; M PHASE CELL CYCLE CHECKPOINTS; NEOPLASM PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION;

EID: 84860375913     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036006     Document Type: Article

References (53)

1. Amos LA, (2000) Focusing-in on microtubules. Curr Opin Struct Biol 10: 236-241.
2. Shi Q, Chen K, Morris-Natschke SL, Lee KH, (1998) Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents. Curr Pharm Des 4: 219-248.
3. Kiselyov A, Balakin KV, Tkachenko SE, Savchuk N, Ivachtchenko AV, (2007) Recent progress in discovery and development of antimitotic agents. Anticancer Agents Med Chem 7: 189-208.
4. Dumontet C, Jordan MA, (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9: 790-803.
5. Cheung CH, Chen HH, Kuo CC, Chang CY, Coumar MS, et al. (2009) Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer 8: 43.
6. Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, et al. (2004) BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 64: 4621-4628.
7. Chen CP, Hu CB, Yeh KC, Song JS, Yeh TK, et al. (2010) Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075. Anticancer Res 30: 2813-2822.
8. Vakifahmetoglu H, Olsson M, Zhivotovsky B, (2008) Death through a tragedy: mitotic catastrophe. Cell Death Differ 15: 1153-1162.
9. Roninson IB, Broude EV, Chang BD, (2001) If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 4: 303-313.
10. Mansilla S, Priebe W, Portugal J, (2006) Mitotic catastrophe results in cell death by caspase-dependent and caspase-independent mechanisms. Cell Cycle 5: 53-60.
11. Kroemer G, Vacchelli E, Vitale I, Galluzzi L, (2011) Cell Death Signaling and Anticancer Therapy. Frontiers in Oncology 1.
12. Vitale I, Galluzzi L, Castedo M, Kroemer G, (2011) Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 12: 385-392.
13. Nabha SM, Mohammad RM, Dandashi MH, Coupaye-Gerard B, Aboukameel A, et al. (2002) Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin Cancer Res 8: 2735-2741.
14. Morse DL, Gray H, Payne CM, Gillies RJ, (2005) Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 4: 1495-1504.
15. Pei L, Melmed S, (1997) Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11: 433-441.
16. Zou H, McGarry TJ, Bernal T, Kirschner MW, (1999) Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285: 418-422.
17. Romero F, Multon MC, Ramos-Morales F, Dominguez A, Bernal JA, et al. (2001) Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res 29: 1300-1307.
18. Tong Y, Eigler T, (2009) Transcriptional targets for pituitary tumor-transforming gene-1. J Mol Endocrinol 43: 179-185.
19. Wang Z, Yu R, Melmed S, (2001) Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol Endocrinol 15: 1870-1879.
20. Wang Z, Moro E, Kovacs K, Yu R, Melmed S, (2003) Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. Proc Natl Acad Sci U S A 100: 3428-3432.
21. Lum PY, Chen Y, Zhu J, Lamb J, Melmed S, et al. (2006) Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes. J Neurochem 97 (Suppl 1): 50-62.
22. Vlotides G, Eigler T, Melmed S, (2007) Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 28: 165-186.
23. Ogbagabriel S, Fernando M, Waldman FM, Bose S, Heaney AP, (2005) Securin is overexpressed in breast cancer. Mod Pathol 18: 985-990.
24. Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, et al. (2000) Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 355: 716-719.
25. Tfelt-Hansen J, Kanuparthi D, Chattopadhyay N, (2006) The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin Med Res 4: 130-137.
26. Chiu SJ, Hsu TS, Chao JI, (2006) Opposing securin and p53 protein expression in the oxaliplatin-induced cytotoxicity of human colorectal cancer cells. Toxicol Lett 167: 122-130.
27. Yu SH, Yang PM, Peng CW, Yu YC, Chiu SJ, (2011) Securin depletion sensitizes human colon cancer cells to fisetin-induced apoptosis. Cancer Lett 300: 96-104.
28. Chiu SJ, Chao JI, Lee YJ, Hsu TS, (2008) Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells. Toxicol Lett 179: 63-70.
29. Karlsson-Rosenthal C, Millar JB, (2006) Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol 16: 285-292.
30. Zhang WH, Poh A, Fanous AA, Eastman A, (2008) DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2. Cell Cycle 7: 1668-1677.
31. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM, (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868.
32. Abraham RT, (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15: 2177-2196.
33. Vogel C, Kienitz A, Hofmann I, Muller R, Bastians H, (2004) Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene 23: 6845-6853.
34. Keyes BE, Yellman CM, Burke DJ, (2008) Differential regulation of anaphase promoting complex/cyclosome substrates by the spindle assembly checkpoint in Saccharomyces cerevisiae. Genetics 178: 589-591.
35. Romero F, Gil-Bernabe AM, Saez C, Japon MA, Pintor-Toro JA, et al. (2004) Securin is a target of the UV response pathway in mammalian cells. Mol Cell Biol 24: 2720-2733.
36. Stemmann O, Zou H, Gerber SA, Gygi SP, Kirschner MW, (2001) Dual inhibition of sister chromatid separation at metaphase. Cell 107: 715-726.
37. Moreno-Mateos MA, Espina AG, Torres B, del Estal MM, Romero-Franco A, et al. (2011) PTTG1/securin modulates microtubule nucleation and cell migration. Mol Biol Cell 22: 4302-4311.
38. Gil-Bernabe AM, Romero F, Limon-Mortes MC, Tortolero M, (2006) Protein phosphatase 2A stabilizes human securin, whose phosphorylated forms are degraded via the SCF ubiquitin ligase. Mol Cell Biol 26: 4017-4027.
39. Ramos-Morales F, Dominguez A, Romero F, Luna R, Multon MC, et al. (2000) Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product. Oncogene 19: 403-409.
40. Davis RJ, (2000) Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
41. De Meyts P, Wallach B, Christoffersen CT, Urso B, Gronskov K, et al. (1994) The insulin-like growth factor-I receptor. Structure, ligand-binding mechanism and signal transduction. Horm Res 42: 152-169.
42. Deacon K, Mistry P, Chernoff J, Blank JL, Patel R, (2003) p38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest. Mol Biol Cell 14: 2071-2087.
43. Xu R, Sato N, Yanai K, Akiyoshi T, Nagai S, et al. (2009) Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells. Anticancer Res 29: 261-270.
44. Jiang RH, Su WC, Liu HF, Huang HS, Chao JI, (2010) Opposite expression of securin and gamma-H2AX regulates baicalein-induced cancer cell death. J Cell Biochem 111: 274-283.
45. Bekier ME, Fischbach R, Lee J, Taylor WR, (2009) Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit. Mol Cancer Ther 8: 1646-1654.
46. Zhou Y, Mehta KR, Choi AP, Scolavino S, Zhang X, (2003) DNA damage-induced inhibition of securin expression is mediated by p53. J Biol Chem 278: 462-470.
47. Pei L, (2000) Activation of mitogen-activated protein kinase cascade regulates pituitary tumor-transforming gene transactivation function. J Biol Chem 275: 31191-31198.
48. Kim DS, Franklyn JA, Smith VE, Stratford AL, Pemberton HN, et al. (2007) Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity. Carcinogenesis 28: 749-759.
49. Fujii T, Nomoto S, Koshikawa K, Yatabe Y, Teshigawara O, et al. (2006) Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. Hepatology 43: 1267-1275.
50. Genkai N, Homma J, Sano M, Tanaka R, Yamanaka R, (2006) Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. Oncol Rep 15: 1569-1574.
51. Chen WS, Yu YC, Lee YJ, Chen JH, Hsu HY, et al. (2010) Depletion of securin induces senescence after irradiation and enhances radiosensitivity in human cancer cells regardless of functional p53 expression. Int J Radiat Oncol Biol Phys 77: 566-574.
52. Liu YN, Liu Y, Lee HJ, Hsu YH, Chen JH, (2008) Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Mol Cell Biol 28: 7096-7108.
53. Hsu TS, Chen C, Lee PT, Chiu SJ, Liu HF, et al. (2008) 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel synthetic compound induces lung carcinoma cell death associated with inhibiting ERK and CDC2 phosphorylation via a p53-independent pathway. Cancer Chemother Pharmacol 62: 799-808.